Abstract
Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Anti-Cancer Agents in Medicinal Chemistry
Title: The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy
Volume: 11 Issue: 2
Author(s): Ludmil Benov, James Craik and Ines Batinic-Haberle
Affiliation:
Keywords: Ortho, meta, and para isomeric Zn(II) N-alkylpyridylporphyrins, photosensitizer, singlet oxygen, photodynamic therapy, cell signaling functions, hyperproliferative tissues, tetrapyrrole ring, lipophilicity/hydrophilicity, methylpyridylporphyrins, transmembrane movement, lysosomes, Immunoblots, hydrophilic analogs, erythrocyte membrane, hydrophobicity, lipophilic components
Abstract: Reactive oxygen species (ROS) are considered to be a main cause for cancer development, but they can also be used for cancer eradication. Because of this dual nature of ROS action, both antioxidant and prooxidant therapeutic agents have been developed and some have shown clinical promise. Selective uptake of porphyrins by malignant cells has for a long time been used for tumor imaging and for targeted delivery of ROS. Redox-active Mn porphyrins can act both as antioxidants and as prooxidants, and may thus be used in anticancer therapy. Porphyrins, which chelate redox inactive metals, for example Zn, demonstrate photo-sensitizing activity and thus can produce singlet oxygen and other reactive oxygen species in cancer cells on irradiation with visible light. Here we review the properties of Zn(II) N-alkylpyridylporphyrin-based photosensitizers, and their ability to damage selected cellular targets.
Export Options
About this article
Cite this article as:
Benov Ludmil, Craik James and Batinic-Haberle Ines, The Potential of Zn(II) N-Alkylpyridylporphyrins for Anticancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/187152011795255975
DOI https://dx.doi.org/10.2174/187152011795255975 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology De Novo Malignancies After Organ Transplantation: Focus on Viral Infections
Current Molecular Medicine Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design Management of Severe Abdominal Infections
Recent Patents on Anti-Infective Drug Discovery Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Endocannabinoid System: A Promising Therapeutic Target for the Treatment of Haematological Malignancies?
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry WT1 Peptide Vaccine as a Paradigm for “Cancer Antigen-Derived Peptide”-Based Immunotherapy for Malignancies: Successful Induction of Anti-Cancer Effect by Vaccination with a Single Kind of WT1 Peptide
Anti-Cancer Agents in Medicinal Chemistry Spirocyclic Nucleosides in Medicinal Chemistry: An Overview
Mini-Reviews in Medicinal Chemistry Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Nano-Neurotherapeutics (NNTs): An Emergent and Multifaceted Tool for CNS Disorders
Current Drug Metabolism Editorial [Hot Topic: Recombinant Immunotoxins – The Next Generation (Executive Editor: Stefan Barth)]
Current Pharmaceutical Design Synthesis and <i>In Silico</i> Studies of C-4 Substituted Coumarin Analogues as Anticancer Agents
Current Computer-Aided Drug Design NAD(P) Biosynthesis Enzymes as Potential Targets for Selective Drug Design
Current Medicinal Chemistry Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Synthetic Retinoids and Their Nuclear Receptors
Current Medicinal Chemistry - Anti-Cancer Agents Biological Activities of Artemisinin Derivatives Beyond Malaria
Current Topics in Medicinal Chemistry Heterocyclic Drug-polymer Conjugates for Cancer Targeted Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry